Literature DB >> 17522713

Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Junia V Melo1, David J Barnes.   

Abstract

Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy; however, the success of new 'designer drugs' is largely restricted to the chronic phase of the disease. If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood. What mechanisms underlie this progression, and are they shared by other common cancers?

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522713     DOI: 10.1038/nrc2147

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  205 in total

1.  PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Authors:  A A Mian; A Rafiei; I Haberbosch; A Zeifman; I Titov; V Stroylov; A Metodieva; O Stroganov; F Novikov; B Brill; G Chilov; D Hoelzer; O G Ottmann; M Ruthardt
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

2.  p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Authors:  Afsar A Mian; Anna Metodieva; Yousef Najajreh; Oliver G Ottmann; Jamal Mahajna; Martin Ruthardt
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 3.  Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.

Authors:  Tomas Radivoyevitch; Lynn Hlatky; Julian Landaw; Rainer K Sachs
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

4.  BCR-ABL signaling: A new STATus in CML.

Authors:  Doriano Fabbro
Journal:  Nat Chem Biol       Date:  2012-02-15       Impact factor: 15.040

5.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 6.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.

Authors:  Walter Kolch; Andrew Pitt
Journal:  Nat Rev Cancer       Date:  2010-08-19       Impact factor: 60.716

Review 7.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

8.  β-Arrestin2 mediates the initiation and progression of myeloid leukemia.

Authors:  Mark Fereshteh; Takahiro Ito; Jeffrey J Kovacs; Chen Zhao; Hyog Young Kwon; Valerie Tornini; Takaaki Konuma; Minyong Chen; Robert J Lefkowitz; Tannishtha Reya
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

9.  Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia.

Authors:  Qian Li; Xiao-Ji Lin; Hui Chen; Jian Gong; Zhen Li; Xiang-Nan Chen
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

10.  BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.

Authors:  Hongfeng Yuan; Zhiqiang Wang; Chunggang Gao; Wengang Chen; Qin Huang; Jiing-Kuan Yee; Ravi Bhatia; WenYong Chen
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.